Defining Genetic Factors for PD in a Conserved Population
Rapid Response Innovation Awards, 2009 - Researcher: Andrew B. Singleton, PhD
https://www.michaeljfox.org/foundation/grant-...ant_id=641

Dr. Singleton is also on the Michael J Fox Foundation Scientific Advisory Board and the Scientific Advisory Board of the Lewy Body Dementia Association

Lysosomal Therapeutics Receives Grant from The Michael J. Fox
Foundation to Fund Parkinson’s Disease Research - December 05, 2014
http://www.evaluategroup.com/Universal/View.a...;id=557743

Biotie awarded USD 2 million grant from The Michael J. Fox Foundation for a clinical study with SYN120 in Parkinson's Disease Dementia - 8 July, 2014
http://globenewswire.com/news-release/2014/07...entia.html

Quote:

---

Agenda:
Advances in Parkinson’s Disease and Lewy Body Dementia
13.35 - Chaired: Ginger Johnson, Vice President, Defined Health

Panellists:
Andrew Singleton , Chief, Molecular Genetics Section and Laboratory of Neurogenetics, NIA, NIH
Gerald Commissiong , President & CEO, Amarantus BioScience Holdings, Inc.
Kees Been, CEO, Lysosomal Therapeutics
Timo Veromaa, President and CEO, Biotie Therapies Corp.
Todd Sherer, CEO, Michael J. Fox Foundation

---